Ovarian cancer has an annual incidence in the UK of just over 5000 women, and the disease still has a poor long-term outlook for the majority of women. The definition of significant, clinically important and clinically available prognostic factors for these patients is important and interesting. Prognostic factors have been identified over the past 10 years, but these have been based on patients being treated at specialist oncology centres (Van Houwelingen et al., 1989; Marsoni et al., 1990) or relate to the preplatin era (Swenerton et al., 1985) . The West Midlands Ovarian Cancer Study Group (WMOCSG), in collaboration with the CRC Trials Unit in Birmingham, have run a succession of phase III clinical trials in ovarian cancer since 1981. A data set to study prognostic factors for patients with gross residual disease remaining after primary surgery for epithelial ovarian cancer was obtained by pooling the patients entered into the first and second West Midlands trials. Patients in whom total macroscopic clearance of disease was achieved at primary surgery were entered into a separate study so this data set comprises all patients fitting the above criteria treated within WMOCSG phase III clinical trials over the 10 year period 1981-91. The first trial evaluated the role of second-look laparotomy (SLL), whole abdominal radiotherapy (Dembo et al., 1979) and chlorambucil following platinum-based chemotherapy (Luesley et al., 1988), while the second trial evaluated the role of intervention debulking surgery (IDS) (Redman et al., 1994) and intensification of chemotherapy. Recruitment into these trials has been good and represents approximately 20% of women with ovarian cancer in the West Midlands; the maximum potential number of eligible patients being estimated from the number of cases occurring within the region over the period, discounting those with non-epithelial tumours, early stage disease or who would not have been fit enough to tolerate platinum-based chemotherapy. This is a 4-fold higher recruitment into clinical trials than the national average, which is estimated to be approximately 5% or less. The long-term follow-up, survival patterns and prognostic factors for this group of 362 patients treated for epithelial ovarian cancer in the West Midlands over the 10 year period 1981-91 are presented. These results suggest that the development of an index to identify good and poor prognostic groups may be possible and could help in targeting optimal therapy for patients with this disease.
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Patients and methods
In the first study 167 patients were given five courses of cisplatin at 100 mg m-2 following primary laparotomy. They were then randomised, stratifying by residual disease after primary surgery (<2 cm or >2 cm), to one of three consolidation treatment arms: (1) second-look laparotomy (SLL) plus radiotherapy; (2) SLL plus 12 courses of chlorambucil; or (3) 12 courses of chlorambucil only. The second-look laparotomy was carried out, where applicable, within 6 weeks of the last course of chemotherapy. The second study investigated intervention debulking surgery (IDS) in patients who had significant amounts of residual disease following primary surgery and subsequently responded to chemotherapy. Patients who were unlikely to benefit from second surgery (i.e. those in whom a total abdominal hysterectomy, bilateral salpingo-oophorectomy and ometectomy had been performed at primary surgery and <2 cm of residual disease remained or those with Stage IV disease) were randomised between the standard chemotherapy (CP) consisting of eight courses of cisplatin 75 mg m2 and cyclophosphamide 750 mg m2 and an alternative non-cross-resistant chemotherapy consisting of three cycles of cisplatin 75 mg m-2, doxorubicin 50 mg m-2 and bleomycin 15 mg m-2 followed by five courses of cyclophosphamide starting at 1 g m-2, increasing by 0.5 g m-2 each course to a maximum of 3 g m-2 (PAB Esc-Cyclo). Patients who were suitable for IDS were randomised in a 2 x 2 factorial design to IDS or no IDS plus either CP or PAB Esc C. As in the first study, the randomisation was stratified by residual disease (<2cm, > 2cm). In 1989, an interim analysis was carried out and showed no significant difference between the two regimens of chemotherapy in terms of survival. The frequency and severity of toxicity was, however, significantly greater in the PAB Esc C arm of the trial and hence randomisation to PAB Esc C was discontinued in July 1989. All patients who entered the study after that date received cisplatin and cyclophosphamide. The results from both trials were reported in 1988 and 1994 respectively (Luesley et al., 1988; Redman et al., 1994) .
Data were collected prospectively from all patients and stored in the ORACLE database on a VAX 11/730 minicomputer at the Cancer Research Campaign Trials Unit. All data manipulation and analyses were carried out on an intentionto-treat basis using SAS statistical software (SAS Institute, SAS Circle, Cary, NC, USA). Survival curves were calculated by the product-limit method (Kalbfleisch and Prentice, 1980) and the log-rank test (Kalbfleisch and Prentice, 1980) was used to test for differences between the curves. Survival has been calculated from the date of randomisation to death for patients who have died and from the date of randomisation to the censor date, 1 January 1993, for those who are still alive.
The Cox proportional hazards method (Cox, 1972) was used to build a multivariate model to identify independent prognostic factors for survival and assess relative risks. The This data set was also analysed adjusting for trial effects. There is no significant differences between the trials (P=0.64) (Figure 2 ) and the results for prognostic factors were identical when the analysis was stratified by trial and by residual disease. Treatments were combined in several different ways to form the large subgroups detailed in Table IV reflects greater adherence to the theory of Griffiths et al. (1979) , claiming improved chemotherapeutic efficacy with residual tumour load of < 2 cm, that improved chemotherapeutic effect is achieved in those where the tumour load is reduced to <2 cm. Reports continue to accumulate in the literature, indicating the effect of platinum rather than tumour volume reduction as influencing survival patterns (Nejit et al., 1991; Venesma et al., 1994) . Griffiths' theory was based on the retrospective analysis of 102 patients, with estimates of tumour volume obtained from the surgical notes in 75% of cases and on questioning the operating surgeon in 25% (Griffiths, 1975) . The accuracy of these estimates remains questionable. Subsequent to this, Griffiths undertook a prospective study indicating improved survival in those patients in whom residual tumour load was reduced to <2 cm. This was based on only 24 patients and in clinical trials would constitute a phase II study (Griffiths and Fuller, 1978) . With such findings the need to progress to a randomised trial is evident -a study which is presently ongoing in the West Midlands.
Patients entered into clinical trials must fit eligibility criteria which may result in the overselection of good prog-N" nostic groups. The national 5 year survival figures for those with stage II, III and IV disease are 45%, 17% and 5% (Cancer Research Campaign, 1991) compared with the results from this analysis of 22%, 14% and 5% respectively. The apparent difference for patients with stage II disease may be because only those with a high risk of recurrence were considered suitable for randomisation.
The model obtained from this analysis shows that this set of patients, whose overall prognosis is poor, can be further subdivided into predicted good and bad prognostic groups. Such a model is, of course, data dependent and may not be generalisable to patients in similar clinical trials or the population of patients with advanced ovarian cancer as a whole. Our results suggest that difference between the predicted survival curves for good and bad prognostic group is large (30% vs 3%) at 5 years and that even for the best prognostic group 5 year survival is poor. In the subset of data used for the Cox regression model (n=213) 20% of patients fell within the good prognosis group and 12% within the bad. It is very important, therefore, that this model is validated fully on other data sets in order to assess the utility of these prognostic factors and predicted survival curves in a clinical setting.
Although data were collected prospectively in these trials there may be other factors that need to be explored in order to improve our understanding of this disease. The identification of clinical interventions which improve outcome is an urgent matter, recognised as such by the Consensus Statement (Allen et al., 1993) , which states that all patients with ovarian cancer should, if possible, be included in therapeutic trials to allow for advances in treatment to be defined as rapidly as possible.
